Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Interleukin-2 in Patients With Type 1 Diabetes
NCT05153070Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2022
- Primary completion
- Nov 2027
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Ciclosporin/ILT-101 with Ciclosporin/placebo (2 arms). Primary endpoint: Variation in Regulatory T cells (Tregs) at Day 67. Started Sep 2022; status: recruiting.
02
Drugs
aldesleukin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05153070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05153070.